EMD Partners with Rules-Based Medicine to Develop and Distribute Multi-Analyte Kits
News Dec 17, 2007
EMD Chemicals (EMD) has announced that it is partnering with Rules-Based Medicine, Inc. (RBM) to develop and distribute high-quality immunoassay products on the Luminex® xMAP® platform under the Novagen brand.
Under the terms of the agreement, RBM is granting EMD/Merck exclusive distribution rights to the largest catalog of quantitative protein multiplex assays currently available.
RBM of Austin, TX, will combine its comprehensive testing content with the international sales and marketing network of EMD/Merck to provide optimized kits that enable researchers to measure hundreds of important biomarkers from serum, plasma and other biological fluids.
“We’re pleased to be working with RBM to bring these highly validated multi-analyte profiling kits to the worldwide market,” said Lisa Johnson, Vice President Corporate Development with EMD.
“Working together, we will leverage the first-class reputation of RBM and their extensive assay content with our global sales and distribution network to deliver a wide range of reproducible and quantitative immunoassay kits to researchers worldwide,” continued Johnson.
“While we’ve been very successful in developing these assays and providing testing services to our clients, we realized that we needed to satisfy the demands of the broader research market by packaging our immunoassay products as kits,” said RBM CEO T. Craig Benson. “EMD/Merck provides the international sales and marketing infrastructure to distribute these kits, co-branded with their well-known and respected Novagen® brand.”
Scheduled for availability in mid-2008, the co-branded kits will be sold to pharmaceutical and biotech companies, and academic institutions. RBM and EMD/Merck will also collaborate to design new products that meet the evolving requirements of their customers.
Animal venoms are the subject of study at research center based at the Butantan Institute in São Paulo. But in this case, the idea is not to find antidotes, but rather to use the properties of the venoms themselves to identify molecular targets of diseases and, armed with that knowledge, develop new compounds that can be used as medicines.